Alembic pharma acquires US based Orit Lab
based Alembic Pharmaceuticals has acquired US-based generic drug developer Orit Laboratories LLC through its 100 percent subsidiary Alembic Pharmaceuticals Inc.
Based out of New Jersey, Orit Laboratories has seven approved and four pending ANDAs, with an 8,600 sq ft wide R&D and pilot manufacturing facility. Orit Laboratories is focused on developing and filing oral solid and liquid products, as per Alembic’s filing on BSE on Wednesday. Apart from existing ANDAs, Orit also brings in soft gelatin-based oral solids and oral liquids to Alembic through a team of eight ‘highly experienced’ scientists.